[go: up one dir, main page]

WO2002072126A3 - Invention relating to hcv diseases - Google Patents

Invention relating to hcv diseases Download PDF

Info

Publication number
WO2002072126A3
WO2002072126A3 PCT/DE2002/000871 DE0200871W WO02072126A3 WO 2002072126 A3 WO2002072126 A3 WO 2002072126A3 DE 0200871 W DE0200871 W DE 0200871W WO 02072126 A3 WO02072126 A3 WO 02072126A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
binding partners
protein
diseases
invention relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2002/000871
Other languages
German (de)
French (fr)
Other versions
WO2002072126A2 (en
Inventor
Norbert Tautz
Christoph Birghan
Heinz-Juergen Thiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transmit Gesellschaft fuer Technologietransfer mbH
Original Assignee
Transmit Gesellschaft fuer Technologietransfer mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transmit Gesellschaft fuer Technologietransfer mbH filed Critical Transmit Gesellschaft fuer Technologietransfer mbH
Priority to AU2002257525A priority Critical patent/AU2002257525A1/en
Publication of WO2002072126A2 publication Critical patent/WO2002072126A2/en
Publication of WO2002072126A3 publication Critical patent/WO2002072126A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the binding partners for the NS2 protein of human Hepatitis C Virus (HCV), to binding partners for a cellular J domain protein (Jiv; J-domain protein interacting with viral protein), and to methods for identifying the binding partners which effect a competitive or allosteric inhibition of the bond between the HCV-NS2 protein and Jiv. The invention also relates to agents for treating HCV diseases that contain said binding partners, and to the use of the binding partners in the prevention, diagnosis and treatment of HCV diseases.
PCT/DE2002/000871 2001-03-14 2002-03-13 Invention relating to hcv diseases Ceased WO2002072126A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002257525A AU2002257525A1 (en) 2001-03-14 2002-03-13 Invention relating to hcv diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10112748A DE10112748A1 (en) 2001-03-14 2001-03-14 Invention relating to HCV diseases
DE10112748.0 2001-03-14

Publications (2)

Publication Number Publication Date
WO2002072126A2 WO2002072126A2 (en) 2002-09-19
WO2002072126A3 true WO2002072126A3 (en) 2002-11-14

Family

ID=7677752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/000871 Ceased WO2002072126A2 (en) 2001-03-14 2002-03-13 Invention relating to hcv diseases

Country Status (3)

Country Link
AU (1) AU2002257525A1 (en)
DE (1) DE10112748A1 (en)
WO (1) WO2002072126A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468527A2 (en) * 1990-07-26 1992-01-29 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines
JPH06141870A (en) * 1992-03-12 1994-05-24 Tokyo Met Gov Rinshiyou Igaku Sogo Kenkyusho Dna fragment capable of coding non-a non-b hepatitic viral antigen
WO1994014974A1 (en) * 1992-12-29 1994-07-07 Akzo Nobel N.V. Monoclonal antibodies and anti-idiotypic antibodies to hepatitis c virus
EP0939128A2 (en) * 1989-09-15 1999-09-01 Oya, Akira, Dr., Director General of the National Institute of Health of Japan, on behalf of The National Institute of Japan New HCV isolates
WO2001016379A1 (en) * 1999-08-30 2001-03-08 Merck & Co., Inc. Hepatitis c virus replication inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939128A2 (en) * 1989-09-15 1999-09-01 Oya, Akira, Dr., Director General of the National Institute of Health of Japan, on behalf of The National Institute of Japan New HCV isolates
EP0468527A2 (en) * 1990-07-26 1992-01-29 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and prevention thereof as vaccines
JPH06141870A (en) * 1992-03-12 1994-05-24 Tokyo Met Gov Rinshiyou Igaku Sogo Kenkyusho Dna fragment capable of coding non-a non-b hepatitic viral antigen
WO1994014974A1 (en) * 1992-12-29 1994-07-07 Akzo Nobel N.V. Monoclonal antibodies and anti-idiotypic antibodies to hepatitis c virus
WO2001016379A1 (en) * 1999-08-30 2001-03-08 Merck & Co., Inc. Hepatitis c virus replication inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DARKE P L ET AL: "INHIBITION OF HEPATITIS C VIRUS NS2/3 PROCESSING BY NS4A PEPTIDES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 49, 3 December 1999 (1999-12-03), pages 34511 - 34514, XP002934074, ISSN: 0021-9258 *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 448 (C - 1240) 22 August 1994 (1994-08-22) *

Also Published As

Publication number Publication date
AU2002257525A1 (en) 2002-09-24
DE10112748A1 (en) 2002-09-19
WO2002072126A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
CY2020003I1 (en) ANTI-IL-12 ANTIBODIES, COMPOSITIONS, METHODS AND USES FOR THE THERAPEUTIC TREATMENT OF CROHN'S DISEASE
WO2006041970A3 (en) Treatment of respiratory syncytial virus (rsv) infection
WO2003057134A8 (en) Specific binding agents of human angiopoietin-2
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
FR16C0028I2 (en) VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
DE60137337D1 (en) PREVENTIVE AND THERAPEUTIC MONOCLONAL ANTIBODIES AGAINST VACCINIAVIRUSANTIGENE
ATE315938T1 (en) 4'-SUBSTITUTED NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS C VIRUS-MEDIATED DISEASES
MXPA03006728A (en) Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions.
BRPI0307673A2 (en) methods of treating vascular disease.
WO2004006858A3 (en) Compounds, compositions, and methods employing same
ATE350375T1 (en) 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
DE60234760D1 (en) PHENYLINDOLE FOR THE TREATMENT OF HIV
PT1427409E (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
WO2005002526A3 (en) Method and compositions for treatment of viral infections
WO2004091436A3 (en) Methods and compositions for treating ocular disease
DE60016047D1 (en) DIHYDROBENZOPYRANE, DIHYDROBENZOTHIOPYRANE AND TETRAHYDROCHINOLINE FOR THE TREATMENT OF COX-2-DEPENDENT DISEASES
MXPA03006776A (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease.
EP1765330A4 (en) Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease
WO2002055560A3 (en) Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
DK1689410T3 (en) Prevention and treatment of hypertensive heart disease by the selective estrogens 8beta-vinyl-estra-1,3,5 (10) -triene-3,17beta-diol and 17beta-fluoro-9alpha-vinyl-estra-1,3,5 (10 ) -triene-3,16alpha-diol
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
DK1530462T3 (en) 1-phenyl-2-dimethylaminomethylcyclohexane compounds for the treatment of depression symptoms. pain and incontinence

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP